1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147141
    HS-276 Inhibitor 98.93%
    HS-276 是一种口服有效且高选择性的 TAK1 抑制剂,Ki 值为 2.5 nM。HS-276 对 TAK1、CLK2、GCK、ULK2、MAP4K5、IRAK1、NUAK、CSNK1G2、CAMKKβ-1 和 MLK1 具有显著抑制作用,IC50 值分别为 8.25、29、33、63、125、264、270、810、1280 和 5585 nM。HS-276 可用于类风湿关节炎 (RA) 研究。
    HS-276
  • HY-B0679
    Lubiprostone

    鲁比前列酮

    Antagonist ≥98.0%
    Lubiprostone (SPI-0211) 通过促进 CIC-2CFTR 的生成和 cAMP 信号通路的激活来增加肠液分泌。Lubiprostone 抑制髓过氧化物酶 (MPO) 活性,下调 Indomethacin (HY-14397) 诱导的 iNOS 和 TNFα 表达。Lubiprostone 可用于慢性便秘研究。
    Lubiprostone
  • HY-N0212
    Peimine

    贝母甲素

    Inhibitor 99.43%
    Peimine (Verticine; Dihydroisoimperialine) 是一种具有口服活性的天然产物。Peimine 具有消炎、镇痛、止咳的作用。Peimine 可用于癌症和炎症相关研究。
    Peimine
  • HY-156454
    UCB-6876 Inhibitor 98.49%
    UCB-6876 是一种 TNFα 抑制剂。UCB-6876 能特异性地与 TNF-α 三聚体的不对称结晶形式结合,KD 为 22 μM。
    UCB-6876
  • HY-134240
    L-Threonic acid magnesium

    L-苏糖酸镁

    Antagonist ≥99.0%
    L-Threonic acid magnesium (Magnesium L-threonate) 是 Threonic acid 的 L 型对映体和 Vitamin C (HY-B0166) 的代谢物。L-Threonic acid magnesium 是一种镁补充剂,可提高脑内镁浓度,抑制 TNF-α/NF-κB 信号通路的激活。L-Threonic acid magnesium 可用于阿尔茨海默病的研究。L-Threonic acid magnesium 具有口服活性。
    L-Threonic acid magnesium
  • HY-P99909
    Elranatamab

    埃纳妥单抗

    Elranatamab (PF-06863135) 是一种抗 CD3E/TNFRSF17 的人源 IgG2κ 单克隆抗体。Elranatamab 的同型对照产品:Human IgG2 kappa, Isotype Control (HY-P99002)。
    Elranatamab
  • HY-P99796
    Ozoralizumab

    奥利组单抗

    Inhibitor 99.80%
    Ozoralizumab (ATN-103) 是一种抗 TNFα 人源化抗体。Ozoralizumab 是一种人源化三价纳米抗体化合物,由两个抗人 TNFα 纳米抗体和一个抗人血清白蛋白 (HSA) 纳米抗体组成。Ozoralizumab 可用于关节炎的研究。
    Ozoralizumab
  • HY-N0635
    Prim-O-glucosylcimifugin

    升麻素苷

    99.94%
    Prim-O-glucosylcimifugin 具有强效的抗炎作用。通过调节 JAK2/STAT3 信号传导可抑制 iNOSCOX-2 表达。
    Prim-O-glucosylcimifugin
  • HY-133807
    Benpyrine Inhibitor 99.26%
    Benpyrine 是一种高度特异性的具有口服活性的 TNF-α 抑制剂,KD 值为 82.1 μM。Benpyrine 与 TNF-α 紧密结合并阻断其与 TNFR1 的相互作用,IC50 值为 0.109 µM。Benpyrine 可用于 TNF-α 介导的炎症和自身免疫性疾病的研究。
    Benpyrine
  • HY-110247
    TRAF-STOP inhibitor 6877002 Inhibitor 99.67%
    TRAF-STOP inhibitor 6877002 是一种选择性 CD40-TRAF6 相互作用抑制剂。TRAF-STOP inhibitor 6877002 通过阻断 CD40-TRAF6 信号通路,抑制经典单核细胞活化、白细胞募集以及巨噬细胞活化和迁移,发挥抗动脉粥样硬化作用。TRAF-STOP inhibitor 6877002 降低经典 NF-κB 通路中信号中间体的磷酸化水平。
    TRAF-STOP inhibitor 6877002
  • HY-W010201
    Citronellol

    香茅醇

    Modulator 98.08%
    Citronellol ((±)-Citronellol) 是一种口服有效的凋亡 (apoptosis) 诱导剂。Citronellol 可以通过调节 ROS-NOMAPK/ERKPI3K/Akt 信号通路预防 6-OHDA 诱导的 SH-SY5Y 细胞帕金森病模型中的氧化应激、线粒体功能障碍和凋亡。Citronellol 可以通过 TNF-α 途径和活性氧 (ROS) 积累诱导人肺癌细胞坏死性凋亡 (necroptosis)。Citronellol 可以降低 LC-3p62 水平来调节自噬 (autophagy) 途径,抑制氧化应激和神经炎症,从而对帕金森大鼠具有神经保护作用。Citronellol 通过抑制麦角甾醇合成从而对红色毛癣菌具有抗真菌 (fungal) 活性。
    Citronellol
  • HY-N0042
    Ginsenoside Rc

    人参皂苷 Rc

    Inhibitor ≥98.0%
    Ginsenoside Rc 是主要的人参皂甙之一,Ginsenoside Rc 增强 GABA 受体 A (GABAA) 介导的离子通道 (IGABA)电流。 Ginsenoside Rc 还抑制 TNF-αIL-1β 表达。
    Ginsenoside Rc
  • HY-147045
    UCB-5307 Inhibitor
    UCB-5307 是一种 TNF 抑制剂,对人 TNFα 的 KD 为 9 nM。UCB-5307 可以穿透预制的 hTNF/hTNFR1 复合物。
    UCB-5307
  • HY-N6607
    Tryptanthrin Modulator 99.89%
    Tryptanthrin 是一种吲哚喹唑啉,可以是产自靛蓝植物的生物碱。Tryptanthrin 是一种口服有效的细胞白三烯 (LT) 生物合成抑制剂。Tryptanthrin 具有抗癌活性。Tryptanthrin 可抑制 NOS1、COX-2、NF-κB 的表达水平,调节 IL-2、IL-10、TNF-α 的表达水平。
    Tryptanthrin
  • HY-N2464
    Maltotetraose

    麦芽四糖

    99.88%
    Maltotetraose 可以作为生物流体中酶联测定淀粉酶活性的一个底物。Maltotetraose 具有口服活性,通过抑制 NF-κB 活性和减少 ICAM-1 表达来降低 TNF-α 诱导的炎症反应。Maltotetraose 还能抑制 PDGF 诱导的血管平滑肌细胞迁移和新生血管形成。此外,Maltotetraose 衍生物 可作为探针,通过靶向细菌麦芽糊精转运蛋白 (maltodextrin transporter) 以检测细菌感染。Maltotetraose 具有良好的长期安全性,有望用于动脉硬化相关疾病研究。
    Maltotetraose
  • HY-N2963
    Broussonin E Inhibitor 98.18%
    Broussonin E 是一种酚类化合物,具有抗炎活性。Broussonin E 可以通过抑制 ERKp38 MAPK,增强 JAK2-STAT3 信号通路,调节巨噬细胞的激活状态来抑制炎症。Broussonin E 可用于动脉粥样硬化等炎症相关疾病的研究。
    Broussonin E
  • HY-P99046
    Selicrelumab

    塞鲁单抗

    Agonist
    Selicrelumab 是一种 CD40 抗体激动剂,可诱导肿瘤微环境的变化。Selicrelumab 可用于胰腺癌的研究和肿瘤新辅助疗法研究。
    Selicrelumab
  • HY-P99653
    Ianalumab

    伊利尤单抗

    Inhibitor 99.97%
    Ianalumab (VAY-736) 是一种针对 BAFF-R 的人源、脱羧化抗体。Ianalumab 能够阻断 BAFF 与 BAFF-R 之间的相互作用,拮抗 BAFF 介导的凋亡保护。Ianalumab 具有抗体依赖性细胞毒性 (ADCC),依赖于免疫受体酪氨酸激活基序 (ITAM) 介导的效应细胞激活。
    Ianalumab
  • HY-N0619
    Mulberroside A

    桑皮苷 A

    Inhibitor 99.86%
    Mulberroside A 是桑树 (Morus alba L.) 中的主要生物活性成分之一。Mulberroside A 可降低 TNF-αIL-1βIL-6 的表达,抑制 NALP3,caspase-1NF-κB 的激活以及 ERKJNK 和 p38 的磷酸化 。Mulberroside A 具有抗炎和抗细胞凋亡作用。Mulberroside A 对蘑菇酪氨酸酶 ( tyrosinase) 具有抑制活性,IC50 为 53.6 μM。
    Mulberroside A
  • HY-B0766
    Bicyclol

    双环醇

    Inhibitor 99.91%
    Bicyclol (SY801) 是一种具有口服活性的传统中药五味子的衍生物,具有多种生物活性,包括抗病毒、抗炎、免疫调节、抗氧化、抗脂肪变性、抗纤维化和抗肿瘤作用。Bicyclol 通过调节热休克蛋白的表达,发挥抗肝细胞凋亡 (apoptosis) 的作用,并抑制 ROS-MAPK-NF-κB 通路的激活,降低丙型肝炎病毒感染肝细胞中 NF-κB 的活化和炎症因子水平,从而预防急性肝损伤中的铁死亡 (Ferroptosis)。此外,Bicyclol 能够改变 Mdr-1、GSH/GSTBcl-2 的表达,提高细胞内抗癌药物浓度,使耐药细胞对抗癌药物增敏,同时调控 PI3K/AKTRas/Raf/MEK/ERK 通路,以抑制人恶性肝癌细胞的增殖。Bicyclol 适用于慢性肝炎、急性肝损伤、非酒精性脂肪性肝病、肝纤维化和肝细胞癌的研究。
    Bicyclol
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.